References of "Petrossians, Patrick"
     in
Bookmark and Share    
Full Text
See detailInfluence of drospirenone on renin-angiotensin-aldosterone system evaluation
VROONEN, Laurent ULg; Cavalier, Etienne ULg; Vranken, Laura ULg et al

in Endocrine Abstracts - 13th European Congress of Endocrinology (2011)

Detailed reference viewed: 34 (5 ULg)
Full Text
Peer Reviewed
See detailHigh prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.
Tichomirowa, Maria A; Barlier, Anne; Daly, Adrian ULg et al

in European Journal of Endocrinology (2011), 165(4), 509-15

BACKGROUND: Aryl hydrocarbon receptor interacting protein (AIP) mutations (AIPmut) cause aggressive pituitary adenomas in young patients, usually in the setting of familial isolated pituitary adenomas ... [more ▼]

BACKGROUND: Aryl hydrocarbon receptor interacting protein (AIP) mutations (AIPmut) cause aggressive pituitary adenomas in young patients, usually in the setting of familial isolated pituitary adenomas. The prevalence of AIPmut among sporadic pituitary adenoma patients appears to be low; studies have not addressed prevalence in the most clinically relevant population. Hence, we undertook an international, multicenter, prospective genetic, and clinical analysis at 21 tertiary referral endocrine departments. METHODS: We included 163 sporadic pituitary macroadenoma patients irrespective of clinical phenotype diagnosed at <30 years of age. RESULTS: Overall, 19/163 (11.7%) patients had germline AIPmut; a further nine patients had sequence changes of uncertain significance or polymorphisms. AIPmut were identified in 8/39 (20.5%) pediatric patients. Ten AIPmut were identified in 11/83 (13.3%) sporadic somatotropinoma patients, in 7/61 (11.5%) prolactinoma patients, and in 1/16 non-functioning pituitary adenoma patients. Large genetic deletions were not seen using multiplex ligation-dependent probe amplification. Familial screening was possible in the relatives of seven patients with AIPmut and carriers were found in six of the seven families. In total, pituitary adenomas were diagnosed in 2/21 AIPmut-screened carriers; both had asymptomatic microadenomas. CONCLUSION: Germline AIPmut occur in 11.7% of patients <30 years with sporadic pituitary macroadenomas and in 20.5% of pediatric patients. AIPmut mutation testing in this population should be considered in order to optimize clinical genetic investigation and management. [less ▲]

Detailed reference viewed: 47 (11 ULg)
Full Text
Peer Reviewed
See detailUne nouvelle forme d'adénomes hypophysaires familiaux : les FIPA-Détection et prise en charge
Beckers, Albert ULg; PETROSSIANS, Patrick ULg; Auriemma, R. S. et al

in Correspondances en MHDN (2011)

Detailed reference viewed: 45 (11 ULg)
Full Text
Peer Reviewed
See detailGenetic susceptibility in pituitary adenomas : from pathogenesis to clinical implications
Jaffrain-Rea, Marie-Lise; Daly, Adrian ULg; Angelini, Mariolina et al

in Expert Review of Endocrinology & Metabolism (2011)

Pituitary adenomas (PA) usually present sporadically, with a multifactorial pathogenesis including somatic mutational events in cancer-related genes. Genetic predisposition implies the presence of ... [more ▼]

Pituitary adenomas (PA) usually present sporadically, with a multifactorial pathogenesis including somatic mutational events in cancer-related genes. Genetic predisposition implies the presence of germline DNA alterations with a variety of impacts on pituitary cell biology, translating into a variable penetrance of the disease. Genetic causes must be considered in the presence of specific clinical settings, such as familial occurrence of PA, with or without extrapituitary diseases, and may also be suspected in young patients with macroadenomas. We <br />review the clinical implications of genetic predisposition, with special attention to Multiple Endocrine Neoplasia type 1 (MEN1), Carney’s complex (CNC) and FIPA (Familial Isolated Pituitary Adenoma), and the scenario of genetic screening in selected patients with an apparently sporadic disease is discussed. [less ▲]

Detailed reference viewed: 148 (45 ULg)
Full Text
Peer Reviewed
See detailA familial pituitary tumor syndromes
Vasilev, Vladimir; Daly, Adrian ULg; PETROSSIANS, Patrick ULg et al

in Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2011), 17(3),

Detailed reference viewed: 14 (5 ULg)
Full Text
See detailImpact of germline AIP mutations on tumor characteristics and Management in young acromegalic patients : results of an age-and tumor diameter matched cohort study
Tichomirowa, Maria A.; Theodoropoulou, Marily; Daly, Adrian ULg et al

in Abstract book - Endo 2011 (2011)

Detailed reference viewed: 16 (5 ULg)
See detailImpact des mutations germinales du gène AIP sur les caractéristiques tumorales et la prise en charge médicale chez les patients acromégales jeunes : résultats d'une étude sur des populations appariées pour l'âge et le diamètre de la tumeur
Beckers, Albert ULg; Tichomirowa, m; Theodoropoulou, M. et al

in Annales d'Endocrinologie - 28ème congrès de la société Française d'Endocrinologie (2011)

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailCaractéristiques des prolactinomes résistants aux agonistes dopaminergiques
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in Annales d'Endocrinologie (2010, September), 71(5), 347

Detailed reference viewed: 37 (4 ULg)
See detailLiège Acromegaly Survey: Data mining in clinical research, or how to seek information vs data
Petrossians, Patrick ULg; Beckers, Albert ULg

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 27 (3 ULg)
See detailHigh prevalence of autoimmune thyroid diseases in patients with prolactinomas
Elenkova, Atanaska ULg; Petrossians, Patrick ULg; Beckers, Albert ULg et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 20 (5 ULg)
See detailACTH silent adenoma shrinking under cabergoline
Petrossians, Patrick ULg; Beckers, Albert ULg

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 12 (2 ULg)
See detailLiège Acromegaly Survey (LAS): First snapshot
Petrossians, Patrick ULg; Chanson, P.; Sievers, C. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 32 (3 ULg)
Full Text
See detailCaractéristiques cliniques et réponses thérapeutiques des patients avec adénome hypophysaire mutés pour AIP : étude internationale sur 96 cas
Beckers, Albert ULg; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 15 (2 ULg)
See detailComprehensive study about the characteristics of 80 dopaminergic agonist resistants prolactinomas
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailMedical Treatment in Cushing’s Syndrome : Dopamine Agonists and Cabergoline
Petrossians, Patrick ULg; Thonnard, Anne-Sophie ULg; Beckers, Albert ULg

in Neuroendocrinology (2010), 92((supp. 1)), 116-19

Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also ... [more ▼]

Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also appear in a number of secretory tumors in various locations, DA agonists have elicited some interest as a medical treatment for hypercorticism. Non-iatrogenic Cushing’s syndromes are due in 70% of the cases to a pituitary adrenocorticotropic hormone (ACTH) producing adenoma, and, less frequently, to an adrenal adenoma or an ectopic ACTH secretion by a neuroendocrine tumor. First-line treatment in Cushing’s syndrome consists of the surgical removal of the secreting tumor. However, surgery may not achieve a complete cure in a number of cases, hence emphasizing the potential benefit of a medical complementary treatment, which could also benefit patients as an alternative approach, either when waiting for, or when the patient is not eligible for surgery. Studies of corticotropic adenomas have shown that 80% of these tumors express D2 receptors. Clinical trials of DA agonists in Cushing’s disease have shown an inhibitory effect of these drugs with an inhibition of ACTH secretion and/or a decrease of tumor size. There are only a few cases of documented use of DA agonists in ectopic ACTH secretion, but when the tumor expresses DA receptors, DA agonists may represent a useful complementary treatment. DA receptors are also expressed in normal and tumoral adrenals, suggesting a potential use of DA agonists in Cushing’s syndrome secondary to adrenal tumors. However, clinical data regarding this specific situation are very scarce, maybe due to the relatively high rate of surgical cure of adrenal adenomas. In conclusion, DA agonists represent a potential preparatory or complementary treatment for endogenous Cushing’s syndrome, especially in Cushing’s disease. These compounds may be underused as suggested by the scarce number of publication and case reports in the literature. In the future, association of these drugs with somatostatin analogs may also prove beneficial. [less ▲]

Detailed reference viewed: 37 (6 ULg)